Comparison of Analgesic Efficacy of Quadratus Lumborum Type 3 and Suprainguinal Fascia Iliaca Compartment Block in Total Hip Arthroplasty Surgery

February 18, 2025 updated by: Muzaffer GENCER, Başakşehir Çam & Sakura City Hospital

Comparison of Analgesic Efficacy of Quadratus Lumborum Type 3 and Suprainguinal Fascia Iliaca Compartment Block in Total Hip Arthroplasty Surgery: a Randomized Controlled Trial

Total Hip Arthroplasty (THA) is a complex surgical procedure frequently performed to treat degenerative conditions in the hip joint. As people's life expectancy increases, the need for hip arthroplasty increases. İnvestigetors aimed to compare the analgesic properties of SIFI and QLB blocks.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • İ̇stanbul
      • Başakşehi̇r, İ̇stanbul, Turkey
        • Basaksehir Cam ve Sakura City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Elective patients scheduled for hip arthroplasty surgery
  2. Patient willingness to participate in the study
  3. Patients over 18 years age of, ASA I-II-III,

Exclusion Criteria:

  1. Patients not wanting to participate in the study
  2. Patients who do not want regional anesthesia technique
  3. Allergic or coagulated patients
  4. Patients with liver, kidney, lung, heart failure and septic patients
  5. Neurological disorder, history of convulsions
  6. ASA IV patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: SIFI Group
Group of 30 patients who underwent SIFI block
Suprainguinal Fascia Iliaca Compartment block was performed with a linear probe placed over the inguinal ligament using a portable ultrasound device. After visualization of the femoral nerve, 30 ml of 0.25% bupivacaine was injected into the fascia iliaca overlying the iliopsoas muscle using an appropriate needle.
Other Names:
  • SIFI
Quadratus Lumborum Type 3 block was performed using a portable ultrasound device with a linear probe placed between the costal margin and the iliac crest on the lateral abdominal wall. 30 ml of 0.25% bupivacaine was injected between the quadratus lumborum and psoas muscles using an appropriate needle.
Other Names:
  • QLB Type 3
Active Comparator: QLB Type 3
Group of 30 patients who underwent QLB block
Suprainguinal Fascia Iliaca Compartment block was performed with a linear probe placed over the inguinal ligament using a portable ultrasound device. After visualization of the femoral nerve, 30 ml of 0.25% bupivacaine was injected into the fascia iliaca overlying the iliopsoas muscle using an appropriate needle.
Other Names:
  • SIFI
Quadratus Lumborum Type 3 block was performed using a portable ultrasound device with a linear probe placed between the costal margin and the iliac crest on the lateral abdominal wall. 30 ml of 0.25% bupivacaine was injected between the quadratus lumborum and psoas muscles using an appropriate needle.
Other Names:
  • QLB Type 3

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect on pain score
Time Frame: At 1,2,4, 6, 12 and 24 hours after surgery
Postoperative 24-hour Visual Analog Scale was measured. ( 0=best 10=worst)
At 1,2,4, 6, 12 and 24 hours after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid Consumption
Time Frame: At 1,2,4, 6, 12 and 24 hours after surgery
Intravenous patient-controlled analgesia (PCA) with tramadol was administered to both groups in the postoperative period.
At 1,2,4, 6, 12 and 24 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2023

Primary Completion (Actual)

June 15, 2023

Study Completion (Actual)

August 1, 2023

Study Registration Dates

First Submitted

February 9, 2025

First Submitted That Met QC Criteria

February 18, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 18, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Opioid Consumption

Clinical Trials on Bupivacain

Subscribe